ANCA Vasculitis and the Complement System, Part 1: The Mouse’s Tale
This episode walks us through the initial research that paved the way for a game changing therapeutic in ANCA vasculitis, as well as the story of how host Adam J. Brown, MD, finally learned how to spell complement.
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.
- Intro :10
- Welcome :21
- Today’s episode :24
- So how did we get there? 4:18
- How do we start teasing apart the effect of the complement in ANCA vasculitis? 8:13
- Discussing and simplifying the mouse model 9:00
- Quickly reviewing the complement cascade 12:06
Brought to you by GSK. Consider the long-term impact of disease activity flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com.
- Taking the puzzle pieces away in the mouse model 17:04
- What about the next steps? 22:05
- What happens when you block C5a? 25:12
- CCX168: Summing up the mouse tale 28:44
- In the next episode 30:20
- Thanks for listening 30:46
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Brilland B, et al. Autoimmun Rev. 2020;19:102424.
Freeley SJ, et al. J Pathol 2016;240:61-71.
Haas M, Eustace JA. Kidney Int 2004;65:2145-2152.
Huugen D, et al. Kidney Int 2007;71:646-654.
Marder SR, et al. Arg. J Immunol. 1985;134:3325-3331.
Schreiber A, et al. J Am Soc Nephrol. 2009;20:289-298.
Xiao H, et al. Am J Pathol. 2007;170:52-64.
Xiao H, et al. J Clin Invest 2002;110:955–963.
Xiao H, et al. J Am Soc Nephrol, 2014;25:225–231.
Collapse
